Tesaro Inc. (TSRO) Is Soaring On Phase 3 Results For Ovarian Cancer Drug

Tesaro Inc. (TSRO) announced Wednesday morning that its Phase 3 trial of niraparib successfully achieved its primary endpoint of progression-free survival in patients with ovarian cancer.

from RTT - Hot Stocks http://ift.tt/29cbRtj
via IFTTT